Navigation Links
EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/6/2008

ting results, our 2006 financial statements also reflect the acquisition of Miikana Therapeutics and the resultant $29.5 million non- cash charge booked as acquired in-process R&D. In 2008, we expect our cash expenses will remain at similar levels as compared to 2007 or increase slightly as a result of supporting ongoing and new clinical trials."

James S. Burns, President and Chief Executive Officer further commented, "These are volatile times in the financial markets and microcap oncology companies such as ours have been hit particularly hard. We are financed adequately and have sufficient cash to fund our clinical and research programs well into 2009. We will continue to pursue a strategy focused on orally- administered, small molecule compounds that can provide us with multiple opportunities to succeed and to mitigate the inherent risk of oncology drug development."

The fourth quarter update call is scheduled for Thursday, March 13, 2008 at 10:00 a.m. ET and will include a question and answer session. To access the live conference, please dial 800-418-7236 (U.S. or Canada) or 973-935-8757 (internationally) and reference conference number 37155333 at least 10 minutes prior to the beginning of the call. A digital recording will be available approximately two hours after completion of the conference and will be accessible for 60 days. To access the recording, dial 800-642-1687 (U.S. or Canada) or 706-645-9291 (internationally) and enter the digital pin number 37155333. This call will not be web cast; however, an audio replay will also be available on the Company's website at http://www.entremed.com approximately one hour after the conclusion of the live conference.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for canc
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed to Present at BIO CEO and Investor Conference
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. QMed, Inc. Reports July Medicare SNP Enrollments
8. Phlo Affiliate Reports Expanded Coverage to Oregon Border
9. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Carrington Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... Canada Endoscopy Visualization Systems Market Outlook ... Canada Endoscopy Visualization Systems market. The report provides ... units) and average prices (in US dollars) within ... Endoscopy Visualization Systems and Low-End Endoscopy Visualization Systems. ... , The report also provides company shares and ...
(Date:7/25/2014)... bacteria live in each person,s digestive tract. Scientists believe ... stave off harmful infections, but their role in human ... light on the role of these bacteria, a team ... recently tracked fluctuations in the bacterial populations of two ... in the July 25 issue of the journal ...
(Date:7/25/2014)... New York (PRWEB) July 25, 2014 ... Market Research, "Biological Drugs Market - Global Industry Analysis, ... the global biological drugs market is estimated at USD ... at a CAGR of 10.1% from 2014 to 2020, ... in 2020. , The biological drugs market is witnessing ...
(Date:7/25/2014)... Livermore, California (PRWEB) July 25, 2014 ... been named to Thomson Reuters list of " The ... Pitz are part of the 3,000 researchers who were ... years to recognize those who published the highest-impact work ... numerous research papers on combustion modeling . , ...
Breaking Biology Technology:Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4
... is a missing link in the capital food chain, and Bill ... devoured by it. , ,Payne, an entrepreneur-in-residence for the Kauffman ... to address the June 25 Wisconsin Alumni Research Foundation's ... the capital food chain for entrepreneurs, and he's familiar with all ...
... have pleaded guilty in Milwaukee to charges of criminal ... $6 million in counterfeit Rockwell Automation computer ... Alice Fisher for the Criminal Division and U.S. Attorney ... announced that Robert Koster of Jonesboro, Ark. pleaded ...
... print still captures the imagination of consumers - even consumers ... clearer example than Blurb . I first discussed Blurb ... than a brief PowerPoint deck. We met at ... unwound a vision for consumer-generated books that well pre-dates the ...
Cached Biology Technology:Investor warns of angel-venture funding gap 2Investor warns of angel-venture funding gap 3Two convicted of selling $6 million in counterfeit Rockwell software on eBay 2Blurb shows that print still captures imaginations 2Blurb shows that print still captures imaginations 3
(Date:7/25/2014)... factor characterized by the existence of numerous isoforms ... to the protein deeply different characteristics. NRG1 plays ... during development and the different phases occurring after ... regrowth, remyelination and target reinnervation, Researchers at the ... soluble NRG1 upregulation observed in Schwann cells immediately ...
(Date:7/25/2014)... tractography (DTT), which is derived from diffusion tensor ... motor tracts, such as the corticospinal tract, the ... The corticospinal tract is known to be a ... human brain. Several studies have reported on injury ... addition, some studies have demonstrated recovery of a ...
(Date:7/25/2014)... MOResearchers at the Stowers Institute for Medical Research ... pheromone receptors, and found pheromones crucial to triggering the ... of receptors helps a male mouse detect pheromones that ... of receptors lets him know if the female mouse ... pheromones are critical to trigger mating. Stowers, researchers believe ...
Breaking Biology News(10 mins):It takes two to court 2It takes two to court 3
... technologies are repairing the human body in ways never ... leaving an increasing population of patients who are newly ... have become a formidable clinical opponent, and foremost among ... a new text from ASM Press. "This ...
... This Christmas season, think twice about spending money on ... good, old-fashioned methodkeeping your tree in a container of ... tree green and healthy. Researchers have determined that some ... fact, in several cases the chemical retardants sped up ...
... In light of recent developments that threaten to lead to ... daily satellite images of the ice shelf available to the ... to monitor the developments as they occur. The Wilkins ... coast of the Antarctic Peninsula, has undergone many changes in ...
Cached Biology News:New text focuses on formidable opportunistic fungus 2Flame retardants prove ineffective on fresh-cut Christmas trees 2
...
...
... monoclonal [F30 P7 D7 F5] to ... tested applications). Antigen: ... Ovalbumin, corresponding to amino acids 462 ... Entrez Gene ID: 6259 ...
Pancreatic Cell Cryopreservation Medium (2X) is intended for the cryopreservation of LT2 Immortalized Pancreatic Mesenchymal Cells (SCR013) and VIT1 Primary Pancreatic Mesenchymal Cells (SCR014)....
Biology Products: